
Insider and congress filings
AbbVie Inc. (ABBV)
NYSE · Healthcare · 369 insider transactions · 202 congress trades · last filed 24 days agoS&P 500
About AbbVie Inc.
from the company's filings and listing, as of Oct 24, 2026- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Robert A. Michael
- Employees
- 57,000
- Listed since
- Jan 2, 2013
- Market value
- $504.8B
- Price to earnings (12 mo)
- 80.5
- Net income per share, as reported (12 mo)
- $3.57
- Dividend yield
- 2.42%
Company news
5 of 9 articles · newest first| Headline | Source | Date |
|---|---|---|
| U.S. FDA approves subcutaneous induction for AbbVie's SKYRIZI in Crohn's diseaseThe induction doses are given by on-body injector at weeks 0, 2, 4 and 8, followed by maintenance doses every eight weeks starting at week 12. | Company release | Oct 23, 2026 |
| AbbVie to present new and updated data at 2026 ESMO Congress in MadridThe presentations cover seven assets across lung, colorectal, ovarian, prostate and gastric cancers. | Company release | Oct 18, 2026 |
| AbbVie presents 20 IBD abstracts with long-term Skyrizi and Rinvoq data at UEGW 2026The company said the meeting runs October 17 to 20 in Barcelona, Spain, and includes new endoscopic remission data for investigational ABBV-466 in Crohn's disease. | Company release | Oct 17, 2026 |
| AbbVie to present 22 inflammatory bowel disease abstracts at ACG 2026 meetingAbbVie said new Phase 3 AFFIRM data showed higher clinical and endoscopic response rates for subcutaneous SKYRIZI than placebo in Crohn's disease patients. | Company release | Oct 11, 2026 |
| AbbVie's Temab-A receives two FDA Breakthrough Therapy DesignationsThe designations cover colorectal cancer and non-small cell lung cancer, and are the first for the drug. | Company release | Oct 7, 2026 |
Written by GetSignal with AI from the company's own SEC filings and press releases; each article links to its source. Not investment advice. All 9 ABBV articles
Earnings
6 reported quarters · next on Oct 30, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Jul 31, 2026 | $3.65 | $3.61 | $17.0B | $16.8B | EPS in lineRevenue in line |
| Q1 FY2026reported Apr 29, 2026 | $2.65 | $2.59 | $15.0B | $14.7B | EPS beatRevenue beat |
| Q4 FY2025reported Feb 4, 2026 | $2.71 | $2.65 | $16.6B | $16.4B | EPS beatRevenue in line |
| Q3 FY2025reported Oct 31, 2025 | $1.86 | $1.77 | $15.8B | $15.6B | EPS beatRevenue in line |
| Q2 FY2025reported Jul 31, 2025 | $2.97 | $2.88 | $15.4B | $15.0B | EPS beatRevenue beat |
| Q1 FY2025reported Apr 25, 2025 | $2.46 | $2.38 | $13.3B | $12.9B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Mar 23, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Robert A. MichaelChairman of the Board and Chief Executive Officer | $1.7M | $13.3M | $17.6M | $32.5M |
| Jeffrey R. StewartExecutive Vice President, Chief Commercial Officer | $1.3M | $5.4M | $8.7M | $15.4M |
| Scott T. ReentsExecutive Vice President, Chief Financial Officer | $1.1M | $4.4M | $6.9M | $12.4M |
| Azita Saleki-GerhardtExecutive Vice President, Chief Operations Officer | $1.1M | $4.0M | $5.8M | $10.8M |
| Roopal B. ThakkarExecutive Vice President, Research & Development and Chief Scientific Officer | $1.1M | $4.0M | $4.8M | $9.9M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $37.6B | 149,488,412 | -0.8% | 8.44% |
| Vanguard Capital Management LLC | $29.0B | 115,396,098 | +0.4% | 6.52% |
| State Street Corp | $20.8B | 82,596,748 | +1.7% | 4.66% |
| Vanguard Portfolio Management LLC | $12.2B | 48,477,996 | -2.1% | 2.74% |
| JPMorgan Chase & Co. | $12.2B | 47,862,796 | -15.6% | 2.70% |
| Geode Capital Management, LLC | $11.8B | 46,998,433 | +0.6% | 2.65% |
| Morgan Stanley | $9.8B | 38,901,001 | +2.3% | 2.20% |
| Capital Research Global Investors | $7.6B | 30,101,551 | -3.7% | 1.70% |
| Norges Bank | $6.4B | 25,554,538 | New | 1.44% |
| Bank of America Corp | $5.3B | 21,237,764 | -11.3% | 1.20% |
| FMR LLC | $5.2B | 20,773,786 | -4.5% | 1.17% |
| Northern Trust Corp | $5.2B | 20,558,447 | -3.1% | 1.16% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
Tracked fund managers holding ABBV
3 managers| Manager | Value | Shares | Share of book |
|---|---|---|---|
| Adage Capital Partners | $402.3M | 1,598,568 | 0.6% |
| Woodline Partners | $228.3M | 907,363 | 0.7% |
| Glenview CapitalLarry Robbins | $37.5M | 148,913 | 0.7% |
3 of the 97 fund managers we track list ABBV shares among the largest positions in their latest 13F, filed for Q2 2026. A manager can hold it further down the book too, so this is a floor, not a count. Share of book is the position against the manager's whole disclosed 13F value.
Open-market insider trades
4 filings shown · newest filing first| Insider | Action | Shares | Price | Value | Trade date | Delay (business days) |
|---|---|---|---|---|---|---|
| Nicholas DonoghoeEVP, Chief BUS/Strat Officer | Sold | 32,710 | $250.00 | $8.2M | Aug 14, 2026filed Aug 18, 2026 | 2d |
| David Ryan PurdueSVP, Controller | Sold | 5,230 | $233.56 | $1.2M | Mar 4, 2026filed Mar 6, 2026 | 2d |
| Perry C. SiatisEVP, GC and Secretary | Sold · scheduled · 3 lines | 18,668 | $234.39 | $4.4M | Mar 2, 2026filed Mar 3, 2026 | 1d |
| Perry C. SiatisEVP, GC and Secretary | Sold · scheduled | 22,381 | $230.00 | $5.1M | Feb 25, 2026filed Feb 27, 2026 | 2d |
One row is one filing, newest filing first. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count. Scheduled: set up in advance under a Rule 10b5-1 trading plan. The delay counts business days from the trade to the filing, the unit of Form 4's two business day deadline: weekends and federal holidays are skipped. How the filing itself works is explained in our guide to Form 4.
Other Form 4 activity (20)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Edward J. RappDirector | Stock award | 129 | Sep 30, 2026 |
| Susan E. QuagginDirector | Stock award | 59 | Sep 30, 2026 |
| Nicholas DonoghoeEVP, Chief BUS/Strat Officer | Option exercise | 32,710 | Aug 14, 2026 |
| Susan E. QuagginDirector | Stock award | 62 | Jun 30, 2026 |
| Edward J. RappDirector | Stock award | 134 | Jun 30, 2026 |
| Roxanne S. AustinDirector | Stock award | 1,118 | May 8, 2026 |
| William H.L. BurnsideDirector | Stock award | 1,118 | May 8, 2026 |
| Jennifer L. DavisDirector | Stock award | 1,118 | May 8, 2026 |
| Thomas C. FreymanDirector | Stock award | 1,118 | May 8, 2026 |
| Brett J. HartDirector | Stock award | 1,118 | May 8, 2026 |
| Melody B. MeyerDirector | Stock award | 1,118 | May 8, 2026 |
| Susan E. QuagginDirector | Stock award | 1,118 | May 8, 2026 |
| Edward J. RappDirector | Stock award | 1,118 | May 8, 2026 |
| Rebecca B. RobertsDirector | Stock award | 1,118 | May 8, 2026 |
| Frederick H. WaddellDirector | Stock award | 1,118 | May 8, 2026 |
| Thomas J. FalkDirector | Stock award | 1,118 | May 8, 2026 |
| Robert J. AlpernDirector | Stock award | 35 | Mar 31, 2026 |
| Edward J. RappDirector | Stock award | 155 | Mar 31, 2026 |
| Susan E. QuagginDirector | Stock award | 71 | Mar 31, 2026 |
| David Ryan PurdueSVP, Controller | Tax withholding | 2,108 | Feb 27, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Congress trades in ABBV
20 disclosures of 202 on record · median 28d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 25, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Pete Sessions | Stock | Sale | $15,001 - $50,000 | +9.1%After the saleS&P 500 -0.1% · +9.2 pts vs S&P 500 | Sep 14, 2026 | Sep 18, 2026 | 4d |
| Alan ArmstrongSelf | Stock | Purchase | $15,001 - $50,000 | +36.4%S&P 500 +19.8% · +16.6 pts vs S&P 500 | Mar 27, 2026 | Jul 21, 2026 | 116d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +32.6%S&P 500 +0.1% · +32.6 pts vs S&P 500 | Jun 2, 2026 | Jul 6, 2026 | 34d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +38.3%S&P 500 +5.4% · +32.8 pts vs S&P 500 | May 1, 2026 | Jun 9, 2026 | 39d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +35.8%S&P 500 +2.8% · +33.0 pts vs S&P 500 | May 15, 2026 | Jun 9, 2026 | 25d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | +38.6%After the saleS&P 500 +5.0% · +33.6 pts vs S&P 500 | May 5, 2026 | Jun 3, 2026 | 29d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +38.3%After the saleS&P 500 +10.8% · +27.6 pts vs S&P 500 | Apr 13, 2026 | May 11, 2026 | 28d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +34.0%After the saleS&P 500 +20.3% · +13.8 pts vs S&P 500 | Mar 30, 2026 | Apr 7, 2026 | 8d |
| Ro Khanna | Stock | Purchase | $15,001 - $50,000 | +30.4%S&P 500 +12.1% · +18.3 pts vs S&P 500 | Feb 5, 2026 | Mar 9, 2026 | 32d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | +30.3%S&P 500 +10.2% · +20.1 pts vs S&P 500 | Jan 23, 2026 | Feb 6, 2026 | 14d |
| Ro Khanna | Stock | Sale | $15,001 - $50,000 | +29.6%After the saleS&P 500 +9.5% · +20.1 pts vs S&P 500 | Jan 29, 2026 | Feb 6, 2026 | 8d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +28.2%After the saleS&P 500 +12.3% · +15.9 pts vs S&P 500 | Dec 18, 2025 | Jan 15, 2026 | 28d |
| Julia LetlowFiled late | Stock | Purchase | $1,001 - $15,000 | +52.0%S&P 500 +31.5% · +20.5 pts vs S&P 500 | Oct 23, 2024 | Jan 13, 2026 | 447d |
| Julia LetlowFiled late | Stock | Sale | $1,001 - $15,000 | +67.7%After the saleS&P 500 +25.0% · +42.8 pts vs S&P 500 | Jan 24, 2025 | Jan 13, 2026 | 354d |
| Julia LetlowFiled late | Stock | Purchase | $1,001 - $15,000 | +48.5%S&P 500 +37.9% · +10.6 pts vs S&P 500 | Apr 28, 2025 | Jan 13, 2026 | 260d |
| Julia Letlow | Stock | Sale | $1,001 - $15,000 | +28.0%After the saleS&P 500 +11.1% · +16.9 pts vs S&P 500 | Dec 8, 2025 | Jan 13, 2026 | 36d |
| Julie JohnsonJoint | Stock | Sale | $1,001 - $15,000 | +23.0%After the saleS&P 500 +13.0% · +9.9 pts vs S&P 500 | Nov 13, 2025 | Dec 11, 2025 | 28d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +25.2%S&P 500 +11.7% · +13.4 pts vs S&P 500 | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +25.2%After the saleS&P 500 +11.7% · +13.4 pts vs S&P 500 | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +31.0%After the saleS&P 500 +11.4% · +19.6 pts vs S&P 500 | Oct 31, 2025 | Nov 21, 2025 | 21d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in ABBV, filterable by party, chamber, type and account.
Members of Congress reporting a position
22 members · estimate, as of Oct 23, 202622 members report a position (estimated). The largest estimated position is in the $500,001 - $1,000,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| John W. Hickenlooper | Democrat · Senate | $500,001 - $1,000,000 | 2.3% |
| J. French Hill | Republican · House | $250,001 - $500,000 | 1.8% |
| Rick W. Allen | Republican · House | $100,001 - $250,000 | 3.4% |
| Gary C. Peters | Democrat · Senate | $100,001 - $250,000 | 3.1% |
| Carol D. Miller | Republican · House | $50,001 - $100,000 | 3.8% |
| Gilbert Ray Cisneros, Jr. | Democrat · House | $50,001 - $100,000 | 0.3% |
| Kelly Morrison | Democrat · House | $50,001 - $100,000 | 0.6% |
| Robert Bresnahan | Republican · House | $50,001 - $100,000 | 0.6% |
| Randy Fine | Republican · House | $50,001 - $100,000 | 4.2% |
| Jared Moskowitz | Democrat · House | $50,001 - $100,000 | 1.3% |
| Tommy Tuberville | Republican · Senate | $50,001 - $100,000 | 1.6% |
| Virginia Foxx | Republican · House | $15,001 - $50,000 | 2.6% |
| Michael A. Rulli | Republican · House | $1,001 - $15,000 | 1.0% |
| Robert J. Wittman | Republican · House | $1,001 - $15,000 | 1.0% |
| Cliff Bentz | Republican · House | $1,001 - $15,000 | 0.6% |
| Daniel Meuser | Republican · House | $1,001 - $15,000 | 0.4% |
| Dwight Evans | Democrat · House | $1,001 - $15,000 | 6.1% |
| John McGuire | Republican · House | $1,001 - $15,000 | 2.1% |
| Julie Johnson | Democrat · House | $1,001 - $15,000 | 0.1% |
| Lucy McBath | Democrat · House | $1,001 - $15,000 | 0.2% |
| Robert B. Aderholt | Republican · House | $1,001 - $15,000 | 1.2% |
| Pete Sessions | Republican · House | $1,001 - $15,000 | 0.1% |
Estimate, as of Oct 23, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Are insiders buying or selling ABBV?
Across the 4 most recent open-market filings shown here, 0 were purchases and 4 were sales. 2 were scheduled in advance under a Rule 10b5-1 plan.
Which members of Congress have traded ABBV?
Pete Sessions, Alan Armstrong, Ro Khanna, Josh Gottheimer, Julie Johnson, Julia Letlow and others disclosed ABBV transactions in the filings shown here.
Which members of Congress hold ABBV?
22 members of Congress report a position in ABBV in the estimate we hold as of Oct 23, 2026. The two largest estimated positions belong to John W. Hickenlooper and J. French Hill; Rick W. Allen holds one of the next largest, in the $100,001 - $250,000 band. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
Is ABBV in the S&P 500 or the Nasdaq 100?
AbbVie Inc. is a current member of the S&P 500, per the membership list we hold as of Oct 26, 2026. Current members of either index get a page here whatever their filing history.
How quickly are ABBV trades disclosed?
Insider filings on this page reached the public a median of 2 business days after the transaction (weekends and federal holidays skipped), against the two business days Form 4 allows. Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.
